To overcome the resistance of T790M, third-generation TKIs are efficacious in EGFR T790M mutation-positive NSCLC, one of which, osimertinib, has been approved by the US Food and Drug Administration (FDA) 16, 17. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.